sorafenibi
Sorafenibi, also known as sorafenib, is an oral multikinase inhibitor used in cancer therapy. It targets several kinases involved in tumor cell proliferation and angiogenesis, most notably the RAF kinases (CRAF/RAF-1 and BRAF) and multiple receptor tyrosine kinases, including VEGFR-2, VEGFR-3, PDGFR-β, FLT3, RET, and KIT. By inhibiting these pathways, sorafenibi aims to slow tumor growth and reduce tumor blood vessel formation.
Indications for sorafenibi include advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. It
Pharmacokinetically, sorafenibi is absorbed after oral administration and has a relatively long terminal half-life. It is
Common adverse effects include hypertension, hand-foot skin reaction, rash, diarrhea, fatigue, and alopecia. Elevations in liver
Brand names include Nexavar, and it is widely used as part of targeted cancer therapy regimens.